ALK-ABELLO AS DK -50
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more
Market Cap & Net Worth: ALK-ABELLO AS DK -50 (4AJ0)
ALK-ABELLO AS DK -50 (F:4AJ0) has a market capitalization of $5.68 Billion (€5.54 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3458 globally and #316 in its home market, demonstrating a -7.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALK-ABELLO AS DK -50's stock price €27.50 by its total outstanding shares 201305917 (201.31 Million).
ALK-ABELLO AS DK -50 Market Cap History: 2015 to 2026
ALK-ABELLO AS DK -50's market capitalization history from 2015 to 2026. Data shows growth from $1.12 Billion to $5.68 Billion (18.81% CAGR).
ALK-ABELLO AS DK -50 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALK-ABELLO AS DK -50's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4AJ0 by Market Capitalization
Companies near ALK-ABELLO AS DK -50 in the global market cap rankings as of March 18, 2026.
Key companies related to ALK-ABELLO AS DK -50 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ALK-ABELLO AS DK -50 Historical Marketcap From 2015 to 2026
Between 2015 and today, ALK-ABELLO AS DK -50's market cap moved from $1.12 Billion to $ 5.68 Billion, with a yearly change of 18.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.68 Billion | -10.07% |
| 2025 | €6.32 Billion | +44.11% |
| 2024 | €4.38 Billion | +59.91% |
| 2023 | €2.74 Billion | +5.40% |
| 2022 | €2.60 Billion | -44.90% |
| 2021 | €4.72 Billion | +42.19% |
| 2020 | €3.32 Billion | +47.16% |
| 2019 | €2.26 Billion | +71.16% |
| 2018 | €1.32 Billion | +30.46% |
| 2017 | €1.01 Billion | -16.87% |
| 2016 | €1.22 Billion | +8.45% |
| 2015 | €1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ALK-ABELLO AS DK -50 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.68 Billion USD |
| MoneyControl | $5.68 Billion USD |
| MarketWatch | $5.68 Billion USD |
| marketcap.company | $5.68 Billion USD |
| Reuters | $5.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.